Literature DB >> 15735567

Usefulness of ascitic fluid cholesterol as a marker for malignant ascites.

Satya V Rana1, Sad G Venkatesh Babu, Rakesh Kocchar.   

Abstract

BACKGROUND: The differential diagnosis of ascites is a common clinical problem. However, the capability to distinguish malignant from non-malignant causes of ascites using available biochemical techniques would obviate many expensive and time-consuming diagnostic studies on patients presenting with ascites of unknown etiology. Therefore, this study was planned to evaluate the diagnostic efficacy of ascitic fluid cholesterol in comparison to the efficiency of ascitic/serum total protein, pH, glucose, total leukocyte count, and the serum/ascitic albumin gradient in differentiating "malignant" from non-malignant ascites. MATERIALS/
METHODS: A total of 50 patients (25 with malignant ascites and 25 with non-malignant) were evaluated for total ascitic protein, ascites/serum (A/S) total protein ratio, serum ascites albumin gradient (SAAG), ascitic pH, serum & ascitic cholesterol with glucose.
RESULTS: The mean ascitic cholesterol level was significantly higher in malignant ascites than in non-malignant ascites, with a cut off level of 70 mg/dl for ascitic fluid cholesterol; 22/25 (88%) patients with malignant ascites could be separated from the 25 patients with non-malignant ascites. The specificity (100%) and diagnostic efficiency (94%) of ascitic fluid cholesterol is better than the 84% specificity and 86% diagnostic efficiency of serum ascitic albumin gradient.
CONCLUSIONS: Total Ascitic protein (70%), Ascitic serum protein ratio (74%), ascitic leukocyte count (54%), and malignant cytology (82%) yielded much lower diagnostic efficiency than ascitic fluid cholesterol (94%) or SAAG (86%) in the diagnosis of malignant ascites.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735567

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  8 in total

1.  Value of combined detection of AFU and TCH in differential diagnosis between malignant and non-tuberculous benign ascites.

Authors:  Hong Zhang; Feng Li; Qun Wei; Yu-Fei Zhu
Journal:  Med Oncol       Date:  2010-11-02       Impact factor: 3.064

2.  Diagnostic accuracy of ascitic cholesterol concentration for malignant ascites: a meta-analysis.

Authors:  Hong Zhu; Yongchun Shen; Kai Deng; Xia Liu; Yaqin Zhao; Taiguo Liu; Ying Huang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  New Biochemical Parameters in the Differential Diagnosis of Ascitic Fluids.

Authors:  Anabela Angeleri; Adriana Rocher; Beatriz Caracciolo; Marcela Pandolfo; Luis Palaoro; Beatriz Perazzi
Journal:  Gastroenterology Res       Date:  2016-03-08

4.  Activation of LXRɑ/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer.

Authors:  Soochi Kim; Maria Lee; Danny N Dhanasekaran; Yong Sang Song
Journal:  BMC Cancer       Date:  2018-12-10       Impact factor: 4.430

5.  Diagnostic Utility of Serum Ascites Lipid and Protein Gradients in Differentiation of Ascites.

Authors:  Mukhyaprana Prabhu; Rahul Sai Gangula; Weena Stanley
Journal:  Int J Hepatol       Date:  2019-06-02

Review 6.  Influence of cholesterol on cancer progression and therapy.

Authors:  Shyamananda Singh Mayengbam; Abhijeet Singh; Ajay D Pillai; Manoj Kumar Bhat
Journal:  Transl Oncol       Date:  2021-03-19       Impact factor: 4.243

7.  Assessment of the diagnostic and prognostic relevance of ACAT1 and CE levels in plasma, peritoneal fluid and tumor tissue of epithelial ovarian cancer patients - a pilot study.

Authors:  Vijayalakshmi Ayyagari; Maio Li; Zvi Pasman; Xinjia Wang; Somaja Louis; Paula Diaz-Sylvester; Kathleen Groesch; Teresa Wilson; Laurent Brard
Journal:  BMC Cancer       Date:  2022-04-10       Impact factor: 4.430

8.  Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients.

Authors:  Hae Kyung Lee; Hiun Suk Chae; Jin Soo Kim; Hyung Keun Kim; Young Seok Cho; Sang Young Rho; Jin-Hyoung Kang; Seok Goo Cho; Hong Seok Jang; Kyungja Han
Journal:  Yonsei Med J       Date:  2008-06-30       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.